Page 4 - Nasdaq Rlmd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq rlmd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Rlmd Today - Breaking & Trending Today

The Manufacturers Life Insurance Company Decreases Stock Position in Relmada Therapeutics, Inc. (NASDAQ:RLMD)

The Manufacturers Life Insurance Company lowered its position in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 17.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 25,037 shares of the company’s stock after selling 5,393 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Relmada Therapeutics were worth $89,000 at the […] ....

United States , Manufacturers Life Insurance Company , Sei Investments Co , Jpmorgan Chase Co , Relmada Therapeutics Inc , Capital Partners , America Corp , Relmada Therapeutics , Get Rating , Visit Holdingschannel , Relmada Therapeutics Daily , Nasdaq Rlmd , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $14.00 Average PT from Analysts

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target […] ....

Relmada Therapeutics Inc , Perceptive Advisors , Relmada Therapeutics Company Profile , Millennium Management , Blackrock Inc , Relmada Therapeutics , Get Rating , Sigma Investments , Relmada Therapeutics Daily , Nasdaq Rlmd ,

Brokerages Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $14.00

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month […] ....

Relmada Therapeutics Company Profile , Vanguard Group Inc , Perceptive Advisors , Blackrock Inc , Relmada Therapeutics Inc , Relmada Therapeutics , Get Rating , Marketbeat Ratings , Vanguard Group , Relmada Therapeutics Daily , Nasdaq Rlmd ,

apricus wealth LLC Sells 30,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD)

Apricus wealth LLC lowered its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 77,329 shares of the company’s stock after selling 30,000 shares during the quarter. apricus wealth LLC owned approximately […] ....

Relmada Therapeutics Inc , Relmada Therapeutics Company Profile , Jpmorgan Chase Co , Proshare Advisors , Citigroup Inc , York Mellon Corp , Advisor Group Holdings Inc , Relmada Therapeutics , Get Rating , Group Holdings , Share Advisors , New York Mellon Corp , Visit Holdingschannel , Relmada Therapeutics Daily , Nasdaq Rlmd , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Zacks Investment Research Upgrades Relmada Therapeutics (NASDAQ:RLMD) to "Hold"

Relmada Therapeutics (NASDAQ:RLMD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release […] ....

New York , United States , Paul Edward Kelly , Securities Exchange Commission , Zacks Investment Research , Swiss National Bank , Deutsche Bank , Relmada Therapeutics Inc , Nisa Investment Advisors , Ameritas Investment Partners Inc , Goldman Sachs Group , Byrne Asset Management , Relmada Therapeutics Company Profile Get Rating , Relmada Therapeutics , Get Rating , Director Paul Edward Kelly , Exchange Commission , Investment Advisors , Investment Partners , Asset Management , National Bank , Therapeutics Company Profile , Nasdaq Rlmd ,